Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia

Journal of Cardiovascular Pharmacology

Volumn 37, Issue 5, 2001, Pages 502-511

  Sabia, Helene ^a   Prasad, Pratapa ^a   Smith, H Tom ^a   Stoltz, Randall R ^b   Rothenberg, Paul ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b GFI Pharmaceutical Services Inc   (United States)

Author keywords

Extended release formulation; Fluvastatin; Hypercholesterolemia; Pharmacokinetics; Safety

Indexed keywords

AMINOTRANSFERASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIRST PASS EFFECT; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; LIPOPROTEINS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED;

EID: 0035038214     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200105000-00002     Document Type: Article

References (21)

1. Fluvastatin: A review of its use in lipid disorders
2. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
3. A randomized placebo-controlled trial of fluvastatin for the prevention of re-stenosis after successful coronary balloon angioplasty: Results of the Fluvastatin Angioplasty Re-stenosis (FLARE) trial
4. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment
5. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers
6. Pharmacokinetics of fluvastatin and specific drug interactions
7. Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors
8. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia
9. High performance liquid chromatography method for the determination of fluvastatin in human plasma
10. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge
11. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4s)
12. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
13. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
14. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of the AFCAPS/TexCAPS
15. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
16. Quantification of menstrual and diurnal periodicities in rates of cholesterol and fat synthesis in humans
17. Updated clinical safety experience with fluvastatin
18. Efficacy and tolerability of fluvastatin in an extended-release delivery system: A pooled analysis of three double-blind, randomized, active-controlled trials in hypercholesterolaemic patients
19. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: A randomized trial
20. Fluvastatin: Pharmacokinetic properties